Quest Pharmatech

Quest Pharmatech PEG

PEG Ratio (Price/Earnings-to-Growth) of Quest Pharmatech (QPT.V) as of Oct 23, 2026.

PEG

0.00

YoY

-103.33%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Quest Pharmatech is 2026 0.00 . PEG Ratio (Price/Earnings-to-Growth) of Quest Pharmatech was 2025 -0.05 . It decreases by -103.33% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Pharmatech Stock analysis

What does Quest Pharmatech do? Quest PharmaTech, Inc. operates as a biotechnology company headquartered in Edmonton, Alberta, focusing on the development and commercialization of antibody-based immunotherapeutic products for cancer. The firm aims to improve the quality of life through its proprietary MAb-AR9.6, which targets MUC16 as a diagnostic agent. This asset is licensed from the University of Nebraska Medical Centre and is currently in the late preclinical stage of development. The company generates value through strategic equity positions in specialized biotechnology entities. Quest PharmaTech holds a 42.5% ownership interest in OncoQuest Inc., a firm developing combinatorial immunotherapy products for cancer treatment. OncoQuest utilizes a technology platform featuring a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G and E class, targeting CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72 to enhance tumor specific immunity. Additionally, the firm maintains a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer within the Greater China territory. These investments allow Quest PharmaTech to extend its reach into specific geographic and therapeutic segments while leveraging the proprietary technologies and platforms of its partner companies. Quest Pharmatech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Pharmatech stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Quest Pharmatech since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Quest Pharmatech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quest Pharmatech

All Key Metrics — Quest Pharmatech